Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060186 | 1.00 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CPOLBSLC6A2 | |
| SCHEMBL1060183 | 1.00 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CPOLBSLC6A2 | |
| SCHEMBL1060180 | 1.00 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CPOLBSLC6A2 | |
| SCHEMBL934627 | 0.82 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1060445 | 0.80 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1060446 | 0.80 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1060447 | 0.80 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL15259815 | 0.79 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL15259814 | 0.79 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL15259817 | 0.79 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454234-B1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9227933-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150126577-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-07 | — | — | US | disclosed |
| US-20110257243-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7994209-B2 | 3-phenoxymethylpyrrolidine compounds | THERAVANCE, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110009465-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126577-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | ADRA2A 64/4885ADRA2B 74/4885ADRA2C 17/4885 |
| US-20110009465-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | ADRA2A 64/4885ADRA2B 74/4885ADRA2C 17/4885 |
| US-20110257243-A1 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS | HTR6, SLC6A4, SLC6A2 | ADRA2A 64/4885ADRA2B 74/4885ADRA2C 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.